92 Participants Needed

BGB-21447 Combinations for Breast Cancer

Recruiting at 16 trial locations
SD
Overseen ByStudy Director
Age: 18+
Sex: Any
Trial Phase: Phase 1
Sponsor: BeiGene
Must be taking: GnRH agonists
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, you must not have had prior exposure to Bcl-2 inhibitors, and you may need to continue or start ovarian function suppression if you are a female participant.

What data supports the effectiveness of the drug BGB-21447 for breast cancer?

The research on similar drugs like alpelisib (BYL-719) shows that it can be effective in treating certain types of breast cancer, especially when combined with other treatments. Alpelisib has been approved for use with fulvestrant in hormone receptor-positive breast cancer, suggesting that drugs targeting similar pathways may also be effective.12345

Is BGB-21447 safe for use in humans?

The safety of buparlisib (BGB-21447) has been evaluated in combination with other treatments for breast cancer, showing it is generally tolerable, but specific side effects or safety concerns are not detailed in the provided studies.14678

What is the purpose of this trial?

The purpose of this study is to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.

Research Team

SD

Study Director

Principal Investigator

BeiGene

Eligibility Criteria

Adults with HR+/HER2- metastatic breast cancer who've had at least two prior treatments, including endocrine therapy and CDK4/6 inhibitors. Women must manage ovarian function suppression; men may need GnRH agonists. Participants should be relatively healthy (ECOG ≤ 1) and willing to use effective birth control during the study.

Inclusion Criteria

My breast cancer is HR+/HER2- and I've had at least 2 treatments for it, including hormone therapy and a CDK4/6 inhibitor.
I am a woman with breast cancer and will start or continue ovarian suppression.
I am a male willing to use hormone therapy if treated with certain breast cancer drugs.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive BGB-21447 in combination with fulvestrant, with or without BGB-43395, to assess safety and tolerability

6 to 9 months
Regular visits for dose escalation and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks
1 visit (in-person)

Long-term follow-up

Participants are monitored for long-term outcomes such as Objective Response Rate and Duration of Response

Approximately 12 months

Treatment Details

Interventions

  • BGB-21447
  • BGB-43395
Trial Overview The trial is testing BGB-21447, a drug aimed at blocking a protein that helps cancer cells survive, combined with fulvestrant. It's also looking at adding another drug, BGB-43395, which inhibits enzymes involved in cell division. The goal is to see if these combinations are safe for patients.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: Part B: BGB-21447 + BGB-43395 + FulvestrantExperimental Treatment3 Interventions
Sequential cohorts of increasing dose levels of BGB-21447 will be evaluated in combination with fulvestrant and BGB-43395.
Group II: Part A: BGB-21447 + FulvestrantExperimental Treatment2 Interventions
Sequential cohorts of increasing dose levels of BGB-21447 will be evaluated in combination with fulvestrant.
Group III: BGB-21447 Food Effect SubstudyExperimental Treatment1 Intervention
Participants will receive BGB-21447 at the recommended dose with a high-fat meal and under a fasted state.

Find a Clinic Near You

Who Is Running the Clinical Trial?

BeiGene

Lead Sponsor

Trials
216
Recruited
32,500+

Findings from Research

The study established the recommended phase 2 doses (RP2D) for alpelisib (350 mg) and buparlisib (100 mg) when combined with tamoxifen and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer, showing that both combinations were well-tolerated.
Patients treated with alpelisib experienced a longer progression-free survival of 25.2 months compared to 20.6 months for those on buparlisib, suggesting that alpelisib may be a more effective option for this patient group.
A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.Lu, YS., Lee, KS., Chao, TY., et al.[2021]
Basal-like triple-negative breast cancer (TNBC) often has an overactive PI3K pathway, making it a target for treatment with BYL-719, a PIK3CA inhibitor that shows promise in combination therapies due to its low drug-drug interaction risk.
In studies using patient-derived xenograft models, BYL-719 was found to work synergistically with 20 different compounds, effectively reducing tumor growth, suggesting that these combinations could be beneficial for treating cancers with PIK3CA mutations or overactive PI3K pathways.
Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs.Boyd, DC., Zboril, EK., Olex, AL., et al.[2023]
CB-103 demonstrated significant anti-tumor activity when combined with fulvestrant in endocrine-resistant ER+ breast cancer models, effectively reducing tumor volume in ESR1-mutant xenografts.
In triple-negative breast cancer (TNBC) models, CB-103 combined with paclitaxel significantly delayed tumor growth and inhibited cancer stem cell formation, suggesting its potential as a treatment option alongside standard chemotherapy.
The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer.Vigolo, M., Urech, C., Lamy, S., et al.[2023]

References

A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. [2021]
Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. [2023]
The Efficacy of CB-103, a First-in-Class Transcriptional Notch Inhibitor, in Preclinical Models of Breast Cancer. [2023]
Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. [2021]
Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer. [2022]
PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. [2023]
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. [2020]
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security